Protein Kinases as Drug Targets (PDF)

INTRODUCTION Signal transduction Inhibitors HIT FINDING AND PROFILING In vitro characterization of small molecule kinase inhibitors Cellular Kinase Inhibition CHEMICAL GENOMICS Dissecting phosphorylation networks: the use of analogue sensitive kinases and more specific kinase inhibitors as tools MEDICINAL CHEMISTRY Compendium of small molecule kinase inhibitors Kinase Inhibitor Lead Technologies Design Principles of Deep Pocket targeting protein kinase inhibitors KINASE INHIBITOR THERAPY Discovery and Design of Protein Kinase Inhibitors: Targeting the cell cycle in Oncology From Discovery to Clinic: Aurora Kinase Inhibitors as Novel Treatments for Cancer Medicinal Chemistry Approaches for the Inhibition of the p38 MAPK Pathway Cellular Protein kinases as antiviral targets Infectious Diseases

Bert Klebl is an expert in small molecule based drug discovery. Currently, he is managing director and CSO of Lead Discovery Center GmbH, which was started by Max-Planck Innovation and the Max-Planck Society. Before, he was at GPC Biotech, Axxima Pharmaceuticals and Aventis (Hoechst Marion Roussel). A biochemist by training, he graduated from the University of Konstanz, Germany, and did post-doctoral work at the Biotechnology Research Institute in Montréal, Canada.

Gerhard Müller received his PhD in Organic Chemistry in 1992 from the Technical University of Munich, working with Horst Kessler. After two years in the Medicinal Chemistry Department of Glaxo Verona (Italy), he joined the Central Research Facility of Bayer AG in Leverkusen. From 2001 to 2003 he headed the chemistry department of Organon's Lead Discovery Unit is Oss, Netherlands. In 2003 he was nominated CSO of Axxima Pharmaceuticals AG in Munich, and upon its acquisition through GPC Biotech AG in 2005, he became GPC's Vice President Drug Discovery. Since 2008 he is CSO and Managing Director of Proteros Fragments GmbH, specializing in fragment-based lead generation. Apart from numerous scientific articles and patents, he co-edited the "Chemogenomics in Drug Discovery" book of this series on medicinal chemistry.

Michael Hamacher studied biology at the Heinrich-Heine-Universität in Düsseldorf, Germany. Subsequent to his PhD, he joined the Medizinisches Proteom-Center, Ruhr-Universität Bochum, Germany, and became Head of Administration of the MPC, responsible for the implementation and the strategical planning of the Human Brain Proteome Project under the roof of the Human Proteome Organisation (HUPO BPP) among others. In 2008, he moved to the Lead Discovery Center GmbH, Dortmund, Germany, for the same position, focussing on preparing national as well as international funding applications, on project management, budgeting as well as human resources. He applied and implemented numerous projects in early

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.